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Vitamin K2 is widely used for the treatment of osteoporosis
in Japan. To understand the effects of vitamin K2 on bone mass
and bone metabolism, we reviewed its effects on the develop-
ment of osteopenia in rats, which characterizes models of
osteoporosis. Vitamin K2 was found to attenuate the increase
in bone resorption and/or maintain bone formation, reduce
bone loss, protect against the loss of trabecular bone mass and
its connectivity, and prevent the decrease in strength of the
long bone in ovariectomized rats. However, combined treat-
ment of bisphosphonates and vitamin K2 had an additive effect
in preventing the deterioration of the trabecular bone architec-
ture in ovariectomized rats, while the combined treatment of
raloxifene and vitamin K2 improved the bone strength of the
femoral neck. The use of vitamin K2 alone suppressed the
increase in trabecular bone turnover and endocortical bone
resorption, which attenuated the development of cancellous
and cortical osteopenia in orchidectomized rats. In addition,
vitamin K2 inhibited the decrease in bone formation in
prednisolone-treated rats, thereby preventing cancellous and
cortical osteopenia. In sciatic neurectomized rats, vitamin K2
suppressed endocortical bone resorption and stimulated bone
formation, delaying the reduction of the trabecular thickness
and retarding the development of cortical osteopenia. Vitamin
K2 also prevented the acceleration of bone resorption and the
reduction in bone formation in tail-suspended rats, which
counteracted cancellous bone loss. Concomitant use of vitamin
K2 with a bisphosphonate ameliorated the suppression of bone
formation and more effectively prevented cancellous bone loss
in tail-suspended rats. Vitamin K2 stimulated renal calcium
reabsorption, retarded the increase in serum parathyroid
hormone levels, and attenuated cortical bone loss primarily by
suppressing bone resorption in calcium-deficient rats while
maintaining the strength of the long bone in rats with
magnesium deficiency. These findings suggest that vitamin K2
may not only stimulate bone formation, but may also suppress
bone resorption. Thus, vitamin K2 could regulate bone
metabolism in rats, which represented the various models of
osteoporosis. However, the effects of vitamin K2 on bone mass
and bone metabolism seem to be modest.
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INTRODUCTION
Vitamin K2 is widely used for the treatment of
osteoporosis in Japan. The up-regulation in the
expression of bone markers in vivo
1 suggests the
anabolic action of vitamin K2. Vitamin K2 is
known to be a cofactor of γ-carboxylase, which
converts the glutamic acid (Glu) residue in osteo-
calcin molecules to γ-carboxyglutamic acid (Gla)
and is, therefore, essential for γ-carboxylation of
osteocalcin.
2-5 Thus, the role of vitamin K2 in bone
formation was thought to be as an essential cofac-
tor for the -carboxylation of osteocalcin. How γ -
ever, recent evidence suggests that vitamin K2 also
has a transcriptional regulatory function.
1 Vitamin
K2 is a transcriptional regulator of bone-specific
genes that acts through steroid and xenobiotic
receptors (SXRs) to favor the expression of osteo-
blastic markers. Thus, the role of vitamin K2 in the
regulation of bone formation may be in the γ-
carboxylation of osteocalcin and the mediation of
osteoblastic marker expression through the use of
SXR, although the exact mechanism remains un-
certain. Therefore, the effects of vitamin K2 on
bone formation are of interest in the treatment
osteoporosis.
However, vitamin K2 has also been reported to
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inhibit the expression of the osteoclast differentia-
tion factor (ODF)/RANK ligand, tartrate-resistant
acid phosphatase activity, and mononuclear cell
formation.
6 In addition, vitamin K2 has induced
osteoclast apoptosis in unfractionated bone cells
and isolated osteoclasts on dentine slices, sug-
gesting that the inhibitory effect of vitamin K2 on
osteoclastic bone resorption may be exerted via
targeting osteoclasts for apoptosis.
7 It has also
been suggested that the inhibitory effect of vita-
min K2 on bone resorption may be independent
of the -carboxylation system, but related to its γ
side chain.
8,9 This line of evidence is substantiated
by the anti-resorptive effect of vitamin K2 on bone
in vitro.
Clinically, vitamin K2 sustains the lumbar bone
mineral density (BMD) and prevents osteoporotic
fractures in patients with postmenopausal osteo-
porosis,
10-12 prevents the loss of the lumbar BMD
partly by inhibiting the reduction in osteopro-
tegerin (OPG)
13 and reduces the incidence of
vertebral fractures in patients with glucocorticoid-
induced osteoporosis,
14-18 increases the metacarpal
BMD in the paralytic upper extremities of patients
with cerebrovascular disease or in elderly women
with Parkinson's disease,
19,20 reduces the incidence
of nonvertebral fractures in elderly women with
Alzheimer's disease when treated with both vita-
min D2 and calcium supplements,
21 and sustains
the lumbar BMD in patients with liver-dysfunc-
tion-induced osteoporosis.
22 Furthermore, vitamin
K deficiency, which is characterized by an in-
creased circulating level of undercarboxylated
osteocalcin and, subsequently, reduced produc-
tion of -carboxylated osteocalcin, may also con γ -
tribute to the risk of osteoporotic fractures.
23-28
Although its effect on BMD may be quite modest,
vitamin K2 may have the potential to regulate
bone metabolism and reduce the risk of osteo-
porotic fractures. Thus, vitamin K2 may be useful
for treating the various types of osteoporosis by
regulating bone formation and resorption. Al-
though it has been recognized that vitamin K2
increases the serum osteocalcin levels, its effect on
bone resorption seems to be less certain. To un-
derstand the effects of vitamin K2 on bone mass
and bone metabolism, we reviewed its effects on
the development of osteopenia in rats, the model
of osteoporosis.
EFFECTS OF VITAMIN K2 ON THE
DEVELOPMENT OF OSTEOPENIA IN RATS
Effects of vitamin K2 in ovariectomized rats
Treatment with vitamin K2 alone
Estrogen deficiency, caused by ovariectomy in
rats, resulted in bone loss due to increased bone
turnover. Several studies have shown the bene-
ficial effects of vitamin K2 on bone loss in ovariec-
tomized rats. Some studies showed that vitamin
K2 prevented early bone loss of the femoral BMD
through the inhibition of bone resorption,
29 at-
tenuated the increase in osteoclastic bone resorp-
tion,
30 maintained the accelerated osteoblastic
activity in the femoral metaphysis,
30 protected
against the loss of trabecular bone mass and its
connectivity in the proximal tibial metaphysis
(Fig. 1),
31 reduced mineralized bone loss in the
lumbar vertebra,
32 and prevented the decrease in
the bone strength of the femoral diaphysis in
ovariectomized rats.
33 However, other studies,
performed by Binkley et al.
34 and Otomo et al.,
35
showed that vitamin K2 did not reduce ovariec-
tomy-associated elevation of bone turnover and
that vitamin K2 did not reduce the distal femoral
BMD, bone mass/density, structure, mineral pro-
perties (mineral-to-matrix ratio), or the bone
strength of the lumbar vertebra and femur. Thus,
because of the modest effects of vitamin K2 on the
bone mass and/or bone metabolism, its effects on
bone loss, formation, and resorption in ovariec-
tomized rats remain controversial. However,
Fig. 1. Three-dimensional µCT images of the proximal
tibial metaphysis in rats [Adopted from the reference 31].
The upper row shows the whole bone and the lower row
shows the same specimens after the removal of the
cortex. Vitamin K2 prevented OVX-induced cancellous
bone loss. OVX, ovariectomy; Sham, sham-operation;
MK-4, menaquinone-4 (menatetrenone: vitamin K2).Skeletal Effects of Vitamin K2 in Rats
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vitamin K2 may have the potential to regulate
bone metabolism, maintain bone strength or
trabecular bone architecture, and at least attenuate
bone loss in ovariectomized rats.
Combined treatment with vitamin K2 and vitamin
D3
A few studies have demonstrated a preventa-
tive effect of this combined treatment on bone loss
in ovariectomized rats. Matsunaga et al. (Fig. 2).
36
and Hara et al.
37 demonstrated that the combined
treatment of 1 -hydroxyvitamin D α 3 and vitamin
K2 was more effective for treating bone mass loss
in the proximal tibial metaphysis and/or the bone
strength of the femoral diaphysis in ovariecto-
mized rats. Although these studies did not clarify
the mechanism underlying the beneficial effects of
this combined treatment on ovariectomy-induced
bone loss, these results illustrated the treatment's
additive effect on osteopenia in ovariectomized
rats.
Combined treatment with vitamin K2 and bisphos-
phonates
A few studies have examined the effects of the
combined treatment of vitamin K2 and bisphos-
phonates on osteopenia that was induced by
ovariectomy. Ito
38 clearly demonstrated that
risedronate prevented the deterioration in the con-
nectivity of the trabeculae in the proximal tibial
metaphysis in ovariectomized rats, whereas
vitamin K2 increased the trabecular thickness.
Thus, the combined treatment of risedronate and
vitamin K2 had an additive effect in preventing
the deterioration of the trabecular bone archi-
tecture in ovariectomized rats.
Combined treatment with vitamin K2 and raloxifene
Iwamoto et al.
39 demonstrated the skeletal
effects of the combined treatment of vitamin K2
and raloxifene in ovariectomized rats. Vitamin K2
alone increased bone formation, whereas ralo-
xifene alone and in combination with vitamin K2
reduced bone turnover. Raloxifene alone, but not
vitamin K2 alone, prevented ovariectomy-induced
bone loss in the distal femoral metaphysis and
proximal tibial metaphysis, as did the vitamin K2
plus raloxifene combination. No significant
beneficial effect of either raloxifene or vitamin K2
alone was observed on the femoral neck bone
strength; however, vitamin K2 plus raloxifene had
greater femoral neck bone strength than the sham-
operated controls (Fig. 3). Thus, raloxifene and
vitamin K2 had complementary effects on bone
resorption and formation activities, respectively,
resulting in a significant improvement in the
femoral neck bone strength.
Effects of vitamin K2 in orchidectomized rats
Testosterone in males is important for skeletal
growth during the period of linear growth and is
Fig. 2. Light micrographs of the proximal tibial metaphysis in rats (magnification × 10) [Adopted from the reference 36].
A. sham, B. OVX (ovariectomy), C. OVX + vitamin K2 supplementation, D. OVX + vitamin D supplementation, and E: OVX
+ vitamin K2 and vitamin D supplementation. Vitamin K2 supplementation did not significantly affect the OVX-induced
cancellous bone loss, while vitamin D supplementation ameliorated it. Combined supplementation of vitamin K2 and
vitamin D prevented OVX-induced cancellous bone loss.Jun Iwamoto, et al.
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responsible for the maintenance of skeletal mass
at a later stage of life.
40-42 Testosterone deficiency,
induced by orchidectomy in rats, induced high-
turnover cancellous osteopenia
43 and cortical
osteopenia with cortical porosity and decreased
periosteal bone formation.
44 A few studies have
reported the beneficial effects of vitamin K2 on the
cancellous and cortical bone mass in orchidec-
tomized rats. Iwamoto et al.
45 showed that orchi-
dectomy in rats induced cancellous and cortical
osteopenia by increasing trabecular and endo-
cortical bone turnover in the proximal tibial
metaphysis. They also showed that vitamin K2 ad-
ministration in orchidectomized rats suppressed
trabecular bone turnover and endocortical bone
resorption, attenuating the development of can-
cellous and cortical osteopenia. This effect of
vitamin K2 on cancellous osteopenia was pri-
marily mediated by its attenuation of the reduc-
tion of the trabecular thickness in these rats. These
results suggest that vitamin K2 may have the
potential to suppress bone resorption or bone
turnover, attenuating cancellous and cortical bone
loss in orchidectomized rats.
Effects of vitamin K2 in glucocorticoid-treated
rats
Glucocorticoid treatment decreased bone for-
mation, which resulted in cortical and cancellous
osteopenia in rats.
46 A few studies have reported
the effects of vitamin K2 on the cancellous and
cortical bones in prednisolone-treated rats. Hara et
al.
47 reported that prednisolone treatment in rats
reduced the tibial length, dry weight, bone den-
sity, femoral length, bone strength, and calcium
content, but vitamin K2 improved these reduc-
tions. Hara et al.
46 also reported that prednisolone
treatment decreased bone formation, resulting in
cancellous and cortical osteopenia in the tibia, and
that vitamin K2 inhibited the decrease in bone
formation, thereby preventing cancellous and
cortical osteopenia (Fig. 4 and 5). The results of
this study suggest that vitamin K2 may have the
potential to prevent bone loss by preventing the
decrease in bone formation, as noted in rats
treated with glucocorticoid.
Effects of vitamin K2 in sciatic neurectomized
rats
Hind-limb immobilization by sciatic neurec-
tomy increased bone resorption and decreased
bone formation, resulting in cancellous and cor-
tical osteopenia in the hind-limb of rats.
45,48,49
Several studies have reported the effects of vita-
min K2 on the cancellous and/or cortical bone
mass in sciatic neurectomized rats. Iwasaki et al.
48
showed that the cancellous bone mass of the
proximal tibial metaphysis was reduced, with a
decrease in bone formation and resorption (bone
turnover) in sciatic neurectomized rats, and that
the administration of vitamin K2 to these rats
increased the cancellous bone mass by preventing
the reduction in bone formation and further
reducing bone resorption. Iwasaki-Ishizuka et al.
49
also showed that sciatic neurectomy in rats was
associated with a transient increase in bone
resorption and a sustained reduction in bone
Fig. 3. Effects of raloxifene and vitamin K2 individually
and in combination on bone strength [Adopted from the
reference 39]. K. OVX + vitamin K2 administration, Ral:
OVX + raloxifene administration. Load-to-failure analyses
were conducted on the femoral neck and L-5 vertebra.
Ultimate loads (N) are plotted as mean ± SEM with sig-
nificant differences with respect to Sham and OVX indi-
cated by "s", and "o", respectively (p< 0.05, Fishers PLSD).
No significant beneficial effect of either raloxifene or
vitamin K2 was observed on the femoral neck bone
strength; however, vitamin K2 plus raloxifene had greater
femoral neck bone strength than sham-operated controls.
Raloxifene and vitamin K2 had complementary effects on
bone resorption and formation activities, respectively,
resulting in a significant improvement of the femoral neck
bone strength. OVX, ovariectomy.Skeletal Effects of Vitamin K2 in Rats
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formation, resulting in a reduction in the BMD of
the femoral distal metaphysis and diaphysis and
also a reduction in the bone strength of the femo-
ral diaphysis, and that vitamin K2 ameliorated
these abnormalities. Iwamoto et al.
45 showed that
sciatic neurectomy in rats increased bone resorp-
tion and decreased bone formation in the cancel-
lous bone. They also showed a decrease in peri-
osteal bone formation and an increase in endocor-
tical bone turnover in the cortical bone, resulting
in cancellous and cortical osteopenia in the tibia.
Vitamin K2 administration in sciatic neurecto-
Fig. 4. Three-dimensional CT images of the proximal tibial metaphysis in rats [Adopted from the reference 46]. The lower μ
row shows the whole bone and the upper row shows the same specimens after the removal of the cortex. Vitamin K2
administration prevented cancellous bone loss that was induced by 3 and 30 mg/kg Pred-treatment. Pred, prednisolone.
Fig. 5. Micrographs of the cross-sections
of the cortical bone of the tibial diaphysis
in rats (magnification × 400) [Adopted
from the reference 46]. The tibial dia-
physis was fixed with 70% alcohol and
embedded in methylmethacrylate after
Villanueva bone staining. It was sectioned
transversely (10 m thickness) at a point μ
2.78 mm from the tibiofibular junction.
Images were scanned by fluorescence
laser microscope. The red lines indicate
the cortical periosteal surface, the green
lines indicate calcein that was taken into
the bone formation area, and the distance
between the double green lines indicates
bone formation width during the 7 day
period. Vitamin K2 administration pre-
vented the decrease in periosteal bone for-
mation that was induced by 3 and 30 mg/
kg Pred-treatment. Pred: prednisolone.Jun Iwamoto, et al.
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mized rats suppressed endocortical bone resorp-
tion and stimulated bone formation and attenu-
ated the reduction of the trabecular thickness,
without any significant effect on the cancellous
bone mass, retarding the development of cortical
osteopenia in the tibia. These results suggest that
vitamin K2 has the potential to suppress bone re-
sorption or bone turnover and/or stimulate bone
formation, attenuating cancellous and cortical
bone loss in the hind-limb of sciatic neurecto-
mized rats.
Furthermore, Iwasaki-Ishizaka et al.
50 demon-
strated that vitamin K2 increased the BMD of the
distal femoral metaphysis by increasing bone
formation and decreasing bone resorption in rats
with sciatic neurectomy induced-bone loss. In
addition, vitamin K2 increased -carboxylated γ
osteocalcin levels and decreased undercarboxyl-
ated osteocalcin levels in the serum. These results
suggest that vitamin K2 improves osteopenia by
improving osteoblast dysfunction and accelerating
-carboxylation of osteocalcin in sciatic neurec γ -
tomized osteopenic rats.
Effects of vitamin K2 in tail-suspended rats
Treatment with vitamin K2 alone
Tail-suspension increased bone resorption and
decreased bone formation in the cancellous bone
and/or decreased bone formation in the cortical
bone, resulting in cancellous and cortical osteo-
penia in the hind-limb of rats.
51-53 In particular,
suppression of bone formation seemed to play a
more important role than the acceleration of bone
resorption.
54 Iwasaki et al.
53 reported that vitamin
K2 prevented the acceleration of bone resorption
and the reduction in bone formation in the tibia
of tail-suspended rats, counteracting the loss of
the BMD or cancellous bone mass. Thus, vitamin
K2 has the potential to suppress bone resorption
and/or stimulate bone formation, attenuating can-
cellous bone loss in the hind-limb of tail-sus-
pended rats.
Combined treatment with vitamin K2 and bisphos-
phonates
Iwasaki et al.
55 demonstrated that incadronate
attenuated cancellous bone loss, by a marked sup-
pression of bone turnover in the proximal tibial
metaphysis of tail-suspended rats, and that the
combination of incadronate and vitamin K2 led to
further attenuation of cancellous bone loss by in-
creasing bone formation, when compared to in-
cadronate alone (Fig. 6). These findings suggest
that the concomitant use of vitamin K2 with
bisphosphonates ameliorated the suppression of
bone formation, which efficiently prevented can-
cellous bone loss in the hind-limb of tail-sus-
pended rats.
Effects of vitamin K2 in rats with calcium-de-
ficiency
Severe calcium imbalance reduces bone mass in
rats. Several studies have reported the beneficial
effects of vitamin K2 on osteopenia and calcium
balance in calcium-deficient rats. Kato et al.
56
reported that a calcium-deficient-diet (low 0.08-
0.1% vs. normal 0.8-1.2%) reduced the femoral
BMD in rats by 12% and that vitamin K2 reversed
calcium-deficiency-induced BMD loss. Iwamoto et
Fig. 6. Two-dimensional CT images of the femoral distal
metaphysis in rats [Adopted from the reference 55]. NS,
non-tail-suspension (control); S, tail-suspension; K, tail
suspension + vitamin K2 administration; B, tail-suspension
+ bisphosphonate (incadronate) administration; BK, tail-
suspension + bisphosphonate (incadronate) and vitamin K2
administration. Vitamin K2 administration attenuated the
tail-suspension-induced cancellous bone loss, whereas
bisphosphoante prevented tail-suspension-induced can-
cellous bone loss. The combined administration of bis-
phosphonate and vitamin K2 was more effective than the
single administration of bisphophonate in increasing
cancellous bone mass.Skeletal Effects of Vitamin K2 in Rats
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al.
57 reported that calcium deficiency (low-calcium
diet: low 0.1% vs. normal 0.5%) in rats induced
hypocalcemia, increased the serum parathyroid
hormone (PTH) and 1,25-dihydroxyvitamin D
levels, decreased the serum 25-hydroxyvitamin D
levels, and stimulated intestinal calcium absorp-
tion and renal calcium reabsorption. Calcium
deficiency also reduced the cortical bone mass of
the tibial diaphysis with decreased periosteal bone
gain and an enlarged marrow cavity. Vitamin K2
stimulated renal calcium reabsorption and re-
tarded the increase in the serum PTH levels in
calcium-deficient rats. However, since there was
no significant change in the serum 1,25-dihy-
droxyvitamin D levels, vitamin K2 did not appear
to have influenced intestinal calcium absorption.
Vitamin K2 also retarded cortical bone loss of the
tibial diaphysis, primarily by suppressing bone
resorption. Robert et al.
58 showed that vitamin K
deficiency in rats induced hypercalciuria, but did
not change the intestinal calcium absorption, and
that vitamin K supplementation in vitamin K-defi-
cient rats corrected hypercalciuria.
Kobayashi et al.
59 demonstrated that severe
calcium/magnesium-deficiency (low-calcium and
magnesium diet: low-calcium 0.01% vs. normal
0.5%; low-magnesium 0.003% vs. normal 0.01%)
decreased the serum calcium and magnesium
levels, as well as the cortical bone mass of the
femur, but increased the serum PTH levels and
renal calcium excretion. Vitamin K2 attenuated
the abnormal decrease in the serum calcium and
magnesium levels and the abnormal increase in
the serum PTH levels and renal calcium
excretion in severe calcium/magnesium-deficient
rats.
Kobayashi et al.
60 also reported that ovariec-
tomy in rats altered calcium balance, resulting in
the decrease in the BMD and the cortical bone
mass of the femoral diaphysis. They further noted
that vitamin K2 supplementation in ovariecto-
mized rats improved calcium balance and pre-
vented reduction of the cortical bone mass.
These findings suggest that vitamin K2 may
have the potential to improve calcium balance,
particularly renal calcium reabsorption, and to
attenuate cortical bone loss in calcium-deficient
rats.
Effects of vitamin K2 in rats with magnesium
deficiency
Magnesium deficiency reduces bone strength
without affecting the cortical bone mass in rats.
61
Kobayashi et al.
61 demonstrated that a low-magne-
sium diet resulted in the reduction of the bone
strength of the femoral diaphysis, despite no sig-
nificant changes in the cortical BMD and cortical
thickness. Vitamin K2 also did not affect the cor-
tical BMD or cortical thickness of the femoral
diaphysis, but it inhibited a decrease in bone
strength.
61 These findings suggest that vitamin K2
may be useful in maintaining bone strength in rats
with magnesium deficiency.
CONCLUSION
We reviewed the effects of vitamin K2 on the
development of osteopenia in rats, the model of
osteoporosis. The rats were either ovariectomized,
orchidectomized, sciatic neurectomized, tail-sus-
pended, glucocorticoid-treated, or calcium-or
magnesium-deficient. It was found that vitamin
K2 could regulate bone metabolism in these rats.
However, the novelty of the observations is some-
what incremental because most of the pre-clinical
animal studies used high-doses of vitamin K2 to
test its pharmacological efficacy for bone. Actu-
ally, the effects of vitamin K2 on bone mass and
bone metabolism seem to be modest. Therefore,
molecular changes in bone metabolism need to be
investigated to determine the exact mechanisms
by which vitamin K2 regulates homeostasis in
bones.
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